Sponsor

Protein Sciences Corporation

Clinical research sponsor

Published trials5

Recruiting shown0

Roles1

SourceClinicalTrials.gov

Clinical trials

5 shown

A Phase I Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160NCT00000745 · collaborator

COMPLETED

A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160NCT00000956 · collaborator

COMPLETED

A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160NCT00000757 · collaborator

COMPLETED

Active Immunization of Asymptomatic, HIV-Infected Individuals With Recombinant GP160 HIV-1 Antigen: A Phase I/II Study of Immunogenicity and ToxicityNCT00000977 · collaborator

COMPLETED

A Phase I/II Dose Escalation Study of Intradermal gp160 to Evaluate Safety, Delayed Type Hypersensitivity (Skin Test) Responses and Immunogenicity in Asymptomatic HIV Seropositive Patients With More Than 400 CD4+ CellsNCT00000667 · collaborator

COMPLETED

Sponsor roles

collaborator5

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.